Regulatory News:
NANOBIOTIX (Euronext : NANO â NASDAQ: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix lead product candidate NBTXR3, a potential first-in-class radioenhancer, in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.
Shanghai and Princeton-based LianBio was founded by Perceptive Advisors with an innovative partnership model to develop and commercialize therapeutics in China and other Asian markets. LianBioâs cross-border development and commercialization expertise includes strong capabilities in oncology and NBTXR3 is the third investigational cancer treatment in the companyâs portfolio. Given the global hi
(1)
LianBio to collaborate in the development of NBTXR3, and contribute to enrollment in five future global registrational studies across several tumor types and therapeutic combinations including immunotherapy
Supports the expansion of global phase III registrational study in head and neck cancer into Greater China, with longer term strategic alignment across multiple tumor indications and therapeutic combinations
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511006169/en/ NANOBIOTIX (Euronext: NANO NASDAQ: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix lead product candidate NBTXR3, a poten
DEUTZ AG: High hopes for 2021 following a successful start to the year for DEUTZ
06.05.2021 · Strong improvement in profitability and free cash flow · Further progress with implementing Transform for Growth; voluntary redundancy program taken up in full · Rigorous implementation of strategic growth initiatives · Full-year guidance for 2021 raised despite difficult supply situation Having finished a year dominated by coronavirus with a much improved fourth quarter in 2020, the uptrend for DEUTZ continued into the first quarter of 2021. This could be seen from the recently published preliminary results, which the Company has confirmed today. The successful start to the year shows that DEUTZ is back on course for growth. Our new orders were up by around a third year on year in the first quarter of 2021, while orders on hand rose by a
Significant new order growth; orders on hand up by around 48 percent year on year Strong improvement in profitability and free cash flow Further progress with implementing Transform for Growth; voluntary